RogerCInhornMDPhD

Oncology • Portland, ME

Medical Director, Mercy Hospital Oncology/Hematology

Join to view full profile

Dr. Inhorn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Inhorn's full profile

Already have an account?

Office
195 Fore River Pkwy
Ste 360
Portland, ME 04102
Phone+1 207-553-6868

Fax+1 207-553-6899

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1994
Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1993
Washington University in St. Louis School of MedicineClass of 1990

Certifications & Licensure

ME State Medical License 2004 - 2026
IL State Medical License 1997 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

70 citations
The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner
Kai Xia, Nishit K. Mukhopadhyay, Roger C. Inhorn, Dwayne L. Barber, P. E. Rose
Proceedings of the National Academy of Sciences of the United States of America. 1996-10-15
114 citations
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic...
Roger C. Inhorn, Jon C. Aster, Sheila A. Roach, Christopher A. Slapak, Robert J. Soiffer
Blood. 1995-04-01
122 citations
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL.
Tetsuya Matsuguchi, Roger C. Inhorn, Nadia Carlesso, Gang Xu, Brian Druker
The EMBO Journal. 1995-01-16

Press Mentions

4 Oncologists on the MoveJanuary 28th, 2022
MaineHealth Launches Comprehensive Medical Oncology Practice in Biddeford, SacoOctober 6th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member